Total lab automation: sample stability of clinical chemistry parameters in an automated storage and retrieval module

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Kobe Vercruysse ◽  
Stijn Lambrecht ◽  
Matthijs Oyaert
Keyword(s):  
Clinical Chemistry ◽  
Fixed Time ◽  
Economic Benefits ◽  
Plasma Samples ◽  
Serum Samples ◽  
Storage And Retrieval ◽  
Sample Stability ◽  
Heparin Plasma ◽  
Variation Database ◽  
Automated Storage

Abstract Objectives Automated storage and retrieval modules (SRM), as part of total lab automation (TLA) systems, offer tremendous practical and economic benefits. In contrast to manual storage systems, SRMs indicate continuous motion of samples and may leave samples prone to temperature fluctuations. This study investigates analyte stability in serum and heparin plasma within an automated storage module. Methods The stability of 28 common biochemistry analytes was investigated using 57 freshly obtained routine serum samples and 42 lithium-heparin plasma samples. Following baseline measurement, samples were stored at 2–8 °C in the automated SRM of the Accelerator a3600 TLA and reanalyzed at fixed time points (2, 4, 8, 12, 24, 48 and 72 h) on the Abbott Architect c16000 chemistry analyzer. The concentration at each time point was expressed as %-difference to the baseline value and mean results were compared to the criteria for desirable bias derived from the biological variation database. Results Nine of the analytes exceeded the bias criterion within 72 h after initial measurement in either serum samples, plasma samples or both. Lithium-heparin plasma samples showed increasing values for phosphor, potassium and lactate dehydrogenase (LDH), which were only considered stable for respectively 24, 12 and 4 h, glucose was considered stable for 8 h. Electrolyte concentrations and LDH activity significantly increased in serum samples beyond 48 h. Bicarbonate should not be performed as add-on test at all. Conclusions The presented data indicate that the conditions within an SRM have no clinical impact on sample stability and allow stable measurement of routine analytes within 72 h, comparable to manual storage facilities.

Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010

2005 ◽  
Vol 43 (11) ◽  
Author(s):  
Francesca Di Serio ◽  
Vincenzo Ruggieri ◽  
Lucia Varraso ◽  
Rosalisa De Sario ◽  
Angela Mastrorilli ◽  
...  
Keyword(s):  
Detection Limit ◽  
Healthy Subjects ◽  
Effect Of Temperature ◽  
Serum Samples ◽  
Coefficients Of Variation ◽  
Sample Stability ◽  
The Matrix ◽  
Heparin Plasma ◽  
Roche Diagnostics ◽  
Age And Sex

AbstractMethods to quantify B-type natriuretic peptide (BNP) and N-terminal-propeptide (NT-proBNP) in plasma or serum samples are well established. We assessed the analytical performance of the Dimension RxL NT-proBNP method (Dade-Behring). Evaluation of different sample types was carried out. Controls and heparin plasma pools were used to determine the detection limit, precision, and linearity. Sample stability and the effect of interfering substances on the NT-proBNP concentrations were evaluated. Agreement between Dimension RxL and Elecsys 2010 (Roche Diagnostics) NT-proBNP methods was assessed. The influence of age and sex on NT-proBNP concentrations was evaluated in healthy subjects. Heparin plasma should be the matrix of choice. The detection limit was 2.0ng/L. The total imprecision was 2.6–3.6% for concentrations from 231 to 9471ng/L; mean NT-proBNP concentrations of 21 and 15ng/L were associated with coefficients of variation of 9.9% and 14.7%, respectively. The method was linear up to 32,650ng/L. There was no effect of temperature, freeze-thaw cycles and interfering substances. A bias was detected when Dimension RxL and Elecsys 2010 NT-proBNP methods were compared. Age and sex were significantly and independently related to NT-proBNP concentrations. The Dimension RxL NT-proBNP method, like the Elecsys 2010, is suitable for routine use in the diagnosis of heart failure.

Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin I

2018 ◽  
Vol 56 (3) ◽  
pp. 492-501 ◽  
Author(s):  
Silvia Masotti ◽  
Concetta Prontera ◽  
Veronica Musetti ◽  
Simona Storti ◽  
Rudina Ndreu ◽  
...  
Keyword(s):  
Cardiac Troponin ◽  
Troponin I ◽  
High Sensitivity ◽  
Cardiac Troponin I ◽  
Analytical Performance ◽  
Analytical Sensitivity ◽  
Plasma Samples ◽  
Serum Samples ◽  
Significant Difference ◽  
Heparin Plasma

AbstractBackground:The study aim was to evaluate and compare the analytical performance of the new chemiluminescent immunoassay for cardiac troponin I (cTnI), called Access hs-TnI using DxI platform, with those of Access AccuTnI+3 method, and high-sensitivity (hs) cTnI method for ARCHITECT platform.Methods:The limits of blank (LoB), detection (LoD) and quantitation (LoQ) at 10% and 20% CV were evaluated according to international standardized protocols. For the evaluation of analytical performance and comparison of cTnI results, both heparinized plasma samples, collected from healthy subjects and patients with cardiac diseases, and quality control samples distributed in external quality assessment programs were used.Results:LoB, LoD and LoQ at 20% and 10% CV values of the Access hs-cTnI method were 0.6, 1.3, 2.1 and 5.3 ng/L, respectively. Access hs-cTnI method showed analytical performance significantly better than that of Access AccuTnI+3 method and similar results to those of hs ARCHITECT cTnI method. Moreover, the cTnI concentrations measured with Access hs-cTnI method showed close linear regressions with both Access AccuTnI+3 and ARCHITECT hs-cTnI methods, although there were systematic differences between these methods. There was no difference between cTnI values measured by Access hs-cTnI in heparinized plasma and serum samples, whereas there was a significant difference between cTnI values, respectively measured in EDTA and heparin plasma samples.Conclusions:Access hs-cTnI has analytical sensitivity parameters significantly improved compared to Access AccuTnI+3 method and is similar to those of the high-sensitivity method using ARCHITECT platform.

scholarly journals Immunoradiometric Assay for Intact Human Osteocalcin(1–49) without Cross-Reactivity to Breakdown Products

1999 ◽  
Vol 45 (4) ◽  
pp. 526-531 ◽  
Author(s):  
John W Colford ◽  
Bruce A Lueddecke ◽  
Michael Salvati ◽  
Dave Hanna ◽  
Dawn Sailer ◽  
...  
Keyword(s):  
Renal Failure ◽  
Solid Phase ◽  
Reference Interval ◽  
Serum Marker ◽  
Cross Reactivity ◽  
Plasma Samples ◽  
Serum Samples ◽  
Calcium Chelation ◽  
Heparin Plasma ◽  
Edta Plasma

Abstract Background: Osteocalcin (Oc), a serum marker of bone turnover, circulates in several forms. We developed an assay for intact human Oc and investigated its clinical features. Methods: We generated goat antibodies and N- and C-terminal Oc. The former was used on solid phase (polystyrene beads), and the latter was used as the tracer in an IRMA. Results: The assay was linear with no cross-reactivity to Oc(1–43), total imprecision (CV) of <10%, and recovery of 100% ± 10%. Assay values for intact Oc in EDTA plasma samples were unchanged at 18–25 °C for 6 h. Values for intact Oc in serum, EDTA plasma, and heparin plasma samples did not change after storage on ice for 8 h. Serum samples from patients with various conditions were stored at −70 or −135 °C for up to 5 years and yielded z-scores comparable to an Oc(1-43) IRMA for all conditions except for renal failure. In renal failure, the Oc(1–43) assay values were increased, whereas the intact assay values were in the reference interval. Conclusion: Decreases in Oc assay values are inhibited by calcium chelation, and slowed by reduced temperatures. The described assay for intact Oc allows improved specificity for bone compared with an assay for Oc(1–43).

Can citrate plasma be used in exceptional circumstances for some clinical chemistry and immunochemistry tests?

Diagnosis ◽  
2019 ◽  
Vol 6 (4) ◽  
pp. 369-375
Author(s):  
Davide Demonte ◽  
Mairi Pucci ◽  
Gian Luca Salvagno ◽  
Giuseppe Lippi
Keyword(s):  
Linear Regression ◽  
Clinical Chemistry ◽  
Plasma Samples ◽  
Dilution Factor ◽  
Heparin Plasma ◽  
Roche Cobas ◽  
Citrate Plasma

Abstract Background The use of alternative sample matrices may be an advantageous perspective when the laboratory falls short of serum or lithium-heparin plasma for performing clinical chemistry and/or immunochemistry testing. This study was aimed at exploring whether some tests may be performed in citrate plasma as an alternative to lithium-heparin plasma. Methods Paired lithium-heparin and citrate plasma samples collected from 55 inpatients were analyzed on Roche Cobas 8000 for 28 different clinical chemistry and immunochemistry parameters. Data obtained in citrate plasma were adjusted for either the dilution factor or using an equation corresponding to the linear regression calculated by comparing unadjusted lithium-heparin and citrate plasma values. Results Except for magnesium (+17%) and sodium (+11%), unadjusted values of all remaining analytes were significantly lower in citrate than in lithium-heparin plasma, with bias ranging between −6.4% and −25.9%. The correlation between lithium-heparin and citrate plasma values was generally excellent (i.e. >0.90). The adjustment of citrate plasma values for the dilution factor (i.e. 1.1) was only effective in harmonizing the results of albumin and lipase, whilst the concentration of all other analytes remained significantly different between the two sample matrices. The adjustment of plasma citrate values using corrective formulas was instead effective in harmonizing all parameters, with no results remaining statistically different between the two sample matrices. Conclusions Citrate plasma may be used in exceptional circumstances for clinical chemistry and immunochemistry testing as a replacement for lithium-heparin plasma, provided that citrate plasma values are adjusted by using validated corrective equations.

High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing

2020 ◽  
Vol 45 (5) ◽  
pp. 491-498
Author(s):  
Fatih Yesildal ◽  
Ferruh Kemal Isman
Keyword(s):  
Ascorbic Acid ◽  
Ldl Cholesterol ◽  
Clinical Chemistry ◽  
Assay Method ◽  
High Dose ◽  
Serum Samples ◽  
Choice Of Treatment ◽  
High Concentrations ◽  
Clinical Chemistry Tests ◽  
Abbott Architect

AbstractObjectiveCOVID-19 pandemia still continues to threaten the whole world. High dose ascorbic acid (AA) infusion is a choice of treatment and its efficiency is still being investigated. AA interferes with many clinical chemistry tests. However, data about the interference of high concentrations of AA is not sufficient. In this study, we aimed to investigate the interference of AA at high concentrations on commonly used chemistry assays.Materials and MethodsSerum samples at AA concentrations of 200, 150, 100, 75, 50, 25, 10, 5, 2 and 0 mg/dL were prepared by using the stock solution of 15000 mg/dL AA. Each sample was analyzed by using the most common 30 chemistry tests (Abbott Architect C8000, Illinois, USA) and a POCT glucometer (STANDARD GlucoNavii, Gyeonggi-do, Republic of Korea).ResultsCreatinine, sodium and glucose (POCT) tests were found to be positively interfered by increasing AA concentrations; while direct bilirubin, lipase, UIBC, triglyceride, total cholesterol, HDL/LDL cholesterol tests were negatively interfered. Absolute interference (%) increased as the AA concentration increased.ConclusionThis is the largest and first study to investigate the interference of high dose AA, which is used in severe COVID-19 patients nowadays. Manufacturers and clinicians should be aware of the possibility of aberrant results due to high dose AA infusion. Clinicians should not forget to consult a laboratory specialist, since he is the only person to monitor the reactions in all assays, and know the technical subjects like interferences, assay method specifications. This issue is very important for correct decision-making and interpretation of the data-mining studies accurately and efficiently.

Search for Melanoma Markers in Plasma and Serum Samples

2005 ◽  
Vol 11 (3) ◽  
pp. 353-360 ◽  
Author(s):  
Roberta Seraglia ◽  
Susanna Vogliardi ◽  
Graziella Allegri ◽  
Stefano Comai ◽  
Mario Lise ◽  
...  
Keyword(s):  
High Frequency ◽  
Healthy Subjects ◽  
Ionic Species ◽  
Low Molecular Weight ◽  
Ionization Mass ◽  
Plasma Samples ◽  
Serum Samples ◽  
Blood Samples ◽  
Melanoma Patients ◽  
Diagnostic Ions

Fourteen blood samples from patients with melanomas and 11 blood samples from healthy subjects were analyzed by matrix-assisted laser desorption/ionization mass spectrometry. The study focussed on species of low molecular weight, in the 800–5000 Da range, present in plasma and sera. While for healthy subjects plasma samples lead to the production of a higher number of ionic species, for melanoma patients a high number of diagnostic ions, present with high frequency and with quite high relative abundance, are present, in particular, in serum samples and, to a lesser extent, also in plasma. Since plasma samples are obtained more easily in comparison to sera, it is possible to suggest that plasma can also be used for these studies.

scholarly journals Multiple products management system with sensors array in automated storage and retrieval systems

2018 ◽  
Vol 297 ◽  
pp. 012052
Author(s):  
Supachai Vongbunyong ◽  
Perawat Roengritronnachai ◽  
Savanut Kongsanit ◽  
Chawisa Chanok-owat ◽  
Pongsakorn Polchankajorn
Keyword(s):  
Management System ◽  
Storage And Retrieval ◽  
Multiple Products ◽  
Retrieval Systems ◽  
Sensors Array ◽  
Automated Storage

Automated Storage and Retrieval of Thin-Section CT Images to Assist Diagnosis: System Description and Preliminary Assessment

Radiology ◽  
2003 ◽  
Vol 228 (1) ◽  
pp. 265-270 ◽  
Author(s):  
Alex M. Aisen ◽  
Lynn S. Broderick ◽  
Helen Winer-Muram ◽  
Carla E. Brodley ◽  
Avinash C. Kak ◽  
...  
Keyword(s):  
Thin Section ◽  
Ct Images ◽  
Preliminary Assessment ◽  
System Description ◽  
Diagnosis System ◽  
Storage And Retrieval ◽  
Automated Storage

scholarly journals Thrombin-Mediated Degradation of Human Cardiac Troponin T

2017 ◽  
Vol 63 (6) ◽  
pp. 1094-1100 ◽  
Author(s):  
Ivan A Katrukha ◽  
Alexander E Kogan ◽  
Alexandra V Vylegzhanina ◽  
Marina V Serebryakova ◽  
Ekaterina V Koshkina ◽  
...  
Keyword(s):  
Sample Preparation ◽  
Serum Sample ◽  
Cardiac Troponin ◽  
Troponin T ◽  
Specific Inhibitor ◽  
Cardiac Troponin T ◽  
Amino Acid Residues ◽  
Serum Samples ◽  
Heparin Plasma ◽  
Normal Human

AbstractBACKGROUNDCardiac troponin T (cTnT) is an acknowledged biomarker of acute myocardial infarction (AMI) that is known to be prone to proteolytic degradation in serum. Such degradation is usually explained by the action of μ-calpain, although there could be other candidates for that role. In the current study, we explored the hypothesis that thrombin-mediated cTnT cleavage occurs as a result of the serum sample preparation.METHODScTnT degradation was studied by using immunoblotting and mass spectrometry (MS) analysis.RESULTSThe comparison of cTnT isolated from AMI heparin plasma and serum samples showed that cTnT in the plasma samples was mainly present as the full-sized molecule (approximately 35 kDa), while in serum samples it was present as a 29-kDa fragment. The incubation of recombinant cTnT, or native ternary cardiac troponin complex with thrombin or in normal human serum (NHS), resulted in the formation of a 29-kDa product that was similar to that detected in AMI serum samples. No cTnT degradation was observed when thrombin or NHS was pretreated with hirudin, a specific inhibitor of thrombin, or during incubation of troponin in normal heparin plasma. When the products of thrombin-mediated cTnT proteolysis were analyzed by MS, 2 fragments consisting of amino acid residues (aar) 2–68 and 69–288 were identified, which suggests that thrombin cleaves cTnT between R68 and S69.CONCLUSIONSThe results of this study suggest that the 29-kDa fragment of cTnT in AMI serum samples mainly appears due to the cleavage by thrombin during serum sample preparation.

Sign in / Sign up

Export Citation Format

Share Document